Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonaprazan vs Esomeprazole for Reflux Esophagitis
NCT06953986Recruiting
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of vonoprazan in reflux esophagitis (3 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Endoscopic healing of reflux esophagitis at 8 weeks. Started Dec 2025; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT06953986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953986.